381 related articles for article (PubMed ID: 26592922)
1. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
3. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine: role and evidence in lymphoma therapy, an overview.
Derenzini E; Zinzani PL; Cheson BD
Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
[TBL] [Abstract][Full Text] [Related]
5. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Gafter-Gvili A; Polliack A
Leuk Lymphoma; 2016; 57(3):512-9. PubMed ID: 26696321
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
8. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
9. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
12. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
[TBL] [Abstract][Full Text] [Related]
15. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Pratt G; Bowcock S; Lai M; Bell S; Bird J; D'Sa S; Cavenagh J; Cook G; Morgan G; Owen R; Snowden JA; Yong K; Davies F;
Int J Lab Hematol; 2014 Feb; 36(1):20-8. PubMed ID: 23615178
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine: mechanism of action and clinical data.
Cheson BD; Leoni L
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 19):1-11. PubMed ID: 22362008
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies.
Hoeg RT; Davis J; Jonas BA; Tuscano J; Rosenberg A; Abedi M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):453-458. PubMed ID: 32171691
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
Palumbo A; Offidani M; Patriarca F; Petrucci MT; Cavo M
Leuk Lymphoma; 2015 Mar; 56(3):559-67. PubMed ID: 24884319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
